FHTX — Foghorn Therapeutics Share News
0.000.00%
Last trade - 00:00- $118.77m
- -$48.81m
- $30.91m
Foghorn slumps as FDA deepens clinical hold on cancer drug trial
Brief: Foghorn Therapeutics Appoints Lynne Parshall To Its Board Of Directors
Brief: Foghorn Therapeutics Inc Provides Second Quarter 2022 Financial and Corporate Update
U.S. STOCKS ON THE MOVE-Kroger Co, Centene, Snap Inc
U.S. STOCKS ON THE MOVE-Revlon, JD.com, Roku
Brief: Foghorn Therapeutics Provides Update On Phase 1 Study Of Fhd-286 In Relapsed And/Or Refractory Aml And Mds
Foghorn tumbles after FDA puts cancer drug trial on partial hold
Brief: Foghorn Therapeutics Inc. - Cash, Cash Equivalents And Marketable Securities Of $424.7 Million, As Of March 31, 2022, Provides Significant Cash Runway
Brief: Foghorn Files Prospectus Supplement Relates To Issuance And Sale Of Shares Of Common Stock Of Up To $200 Million From Time To Time
Brief: Foghorn Therapeutics Provides Full Year 2021 Corporate Update And 2022 Outlook
Brief: Foghorn Therapeutics Files For Mixed Shelf Of Up To $300 Million - SEC Filing
U.S. RESEARCH ROUNDUP- Avalara, Beyond Meat, Portillos
U.S. STOCKS ON THE MOVE-Arena Pharma, Harley-Davidson, U.S. banks, travel stocks
U.S. STOCKS ON THE MOVE-Novavax, Harley-Davidson, Peloton, Arena Pharma
Foghorn jumps on Lilly collaboration for cancer treatment
Brief: Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets
Foghorn Therapeutics Inc. reports results for the quarter ended in June - Earnings Summary
Brief: Foghorn Therapeutics Inc Says Reported Cash, Cash Equivalents And Marketable Securities Of $141.3 Mln As Of June 30, 2021
Brief: Foghorn Therapeutics Says Received IND Clearance For FHD-609